title: FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer.
abstract: OBJECTIVE
  This study is designed to evaluate the expression and prognostic value of FGFR3 protein expression in patients with pTa/pT1 tumours and to determine the significance of the combinations of FGFR3 and p53 protein expressions in bladder pathogenesis.
  
  
  METHODS
  A tissue microarray (TMA) of 107 pTa, and 147 pT1 tumours was constructed. The TMA sections were immunostained with FGFR3 and p53 monoclonal antibodies.
  
  
  RESULTS
  There were significant associations between loss of FGFR3 and tumour stage (p<0.001) and grade (p<0.001) and between p53 overexpression and tumour stage and grade (p<0.001 and p<0.001, respectively). There was no association between FGFR3 and p53 proteins (p=0.107). In addition, tumours with FGFR3+/p53- phenotype have slower recurrence rate than other (FGFR3+/p53+, FGFR3-/p53- and FGFR3-/p53+).
  
  
  CONCLUSIONS
  1-FGFR3 expression is significantly associated with two important prognostic factors; stage and grade. 2-FGFR3 protein expression is not an independent predictive factor for pTa/pT1 tumour recurrence and progression. 3-Tumours with FGFR3+/p53- phenotype seem to have a distinctive pathway in bladder tumorigenesis.
authors.affiliation: Department of Pathology and Laboratory Medicine, Roswell Park Cancer Institute, Elm and Carlton Street, Buffalo, NY 14263, USA. pmhawech1@yahoo.com
authors.forename: P
authors.initials: P
authors.lastname: Mhawech-Fauceglia
authors.forename: R T
authors.initials: RT
authors.lastname: Cheney
authors.forename: G
authors.initials: G
authors.lastname: Fischer
authors.forename: A
authors.initials: A
authors.lastname: Beck
authors.forename: F R
authors.initials: FR
authors.lastname: Herrmann
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D000911:Antibodies, Monoclonal; D002295:Carcinoma, Transitional Cell / Q000737:chemistry* / Q000473:pathology / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000737:chemistry; D009367:Neoplasm Staging; D010641:Phenotype; D011379:Prognosis; D051498:Receptor, Fibroblast Growth Factor, Type 3 / Q000032:analysis* / Q000276:immunology; D012189:Retrospective Studies; D016159:Tumor Suppressor Protein p53 / Q000032:analysis* / Q000276:immunology; D001749:Urinary Bladder Neoplasms / Q000737:chemistry* / Q000473:pathology / Q000628:therapy; D013520:Urologic Surgical Procedures
chemical_list: D000911:Antibodies, Monoclonal; D016159:Tumor Suppressor Protein p53; C496365:FGFR3 protein, human; D051498:Receptor, Fibroblast Growth Factor, Type 3